Chiron’s 2nd-Quarter Profit Rises 23%

Chiron Corp., the third-biggest U.S. biotechnology company, said second-quarter profit climbed 23% as it sold more vaccines and blood tests.

Net income increased to $62 million, or 33 cents a share, from $50.4 million, or 26 cents, a year earlier, and revenue rose 17% to $350.3 million, the Emeryville, Calif.-based firm said.

Shares of Chiron, which announced its financial results after the close of U.S. markets, rose 63 cents to $48.15 on Nasdaq.